Medtronic to acquire Contego Medical in $380 million deal

In this news:

Key takeaways

  • Medtronic plans to buy Contego Medical for $380 million, with potential payments after the acquisition.
  • The deal is expected to be minimally dilutive to adjusted EPS in FY27 and FY28.
  • It includes the FDA-approved Neuroguard IEP Direct System and Excipio thrombectomy devices.

Medtronic announced on Nov. 16, 2026 its intent to acquire Contego Medical, a privately held medical device company, in a Medtronic deal valued at $380 million with potential payments post-acquisition. Contego focuses on carotid artery disease and peripheral thrombectomy.

According to the release, the acquisition builds on an exclusive US distribution agreement with Contego, first announced in January 2025. It advances the Medtronic strategy of targeted investments that strengthen its core franchises.

Medtronic deal: the details

  • Consideration (cash / stock / assumed debt): Valued at $380 million with potential payments post-acquisition
  • What is acquired or divested: Contego Medical, including the Neuroguard IEP Direct System and Excipio thrombectomy devices
  • Guidance after close: Minimally dilutive to Medtronic adjusted EPS in FY27 and FY28 and neutral to accretive thereafter
  • Closing conditions and timing: Third quarter of Medtronic’s fiscal year, subject to customary closing conditions

“With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease,” said David Moeller, senior vice president and president of Medtronic Peripheral Vascular Health.

“Deepening our partnership with Medtronic is an exciting next chapter,” said Ravish Sachar, MD, Founder and Chief Executive Officer of Contego Medical.

“Our planned acquisition of Contego builds on that commitment, helping physicians bring meaningful innovation to more patients with carotid artery disease,” said Linnea Burman, senior vice president and president of Medtronic Neurovascular.

The planned acquisition includes the recently FDA-approved Neuroguard IEP Direct System, Medtronic said. The company called it the first and only transcarotid artery revascularization system with integrated embolic protection (TCAR-IEP) in addition to flow reversal. In the prospective, multicenter PERFORMANCE III study, the system showed zero strokes, zero neurological deaths, zero cranial nerve injuries and zero myocardial infarctions at 30 days.

The deal also includes Contego’s Excipio thrombectomy devices, according to the release. They complement Medtronic’s Liberant thrombectomy system in treating peripheral vascular disease.

Carotid artery disease occurs when the carotid arteries, which supply the brain, become narrowed or blocked, the release said. Plaque can rupture or embolize and lead to a stroke, accounting for about 20% of ischemic strokes. Embolic debris released during carotid revascularization can contribute to procedural stroke risk.

Background to the Medtronic deal

Medtronic plc is a healthcare technology company headquartered in Galway, Ireland, according to the release. It has a team of 90,000+ people across more than 150 countries. Its technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools and patient monitoring systems. Contego Medical’s investors include Hatteras Venture Partners, U.S. Venture Partners, Lightstone Ventures and Amzak Health.

What this means

Medtronic said the deal turns an existing distribution partnership into ownership of Contego’s carotid and thrombectomy lines. The transaction still awaits customary closing conditions, and the potential payments post-acquisition remain part of its value.

Analysis

The acquisition converts a distribution relationship, first announced in January 2025, into full ownership, which could give Medtronic more control over Contego’s carotid technology. The PERFORMANCE III results at 30 days likely underpin the company’s aim to lead in carotid revascularization.

For MDT holders, the financial effect appears modest: Medtronic projects minimal adjusted EPS dilution in FY27 and FY28, then neutral to accretive results. Open points include the size and conditions of potential payments post-acquisition and completion of customary closing conditions.

What to watch

  • 2026-11-24: MDT reports quarterly results. Management may update investors on the Contego acquisition and its expected EPS effect.
  • Third quarter of its fiscal year: Expected closing of the Contego Medical acquisition. Closing depends on customary conditions and brings Contego’s devices into Medtronic.
  • Potential payments post-acquisition. These payments form part of the deal’s stated value.

The crypto angle

Medtronic Plc has 4 tokenized versions across 5 known blockchains: Arbitrum One, BNB Smart Chain, Ethereum, Solana, and Morph.

Source: cryptobriefing.com

Share the article:

Top Trending Cryptocurrencies on The Market

Current Price

$1.011

7 Days
MGLO 7 days: +0%

Market Cap

$188.9M 0.00%

24h Volume

-

Supplies

186.8M / ∞

Current Price

$0.9976

7 Days
USAT 7 days: -0.07%

Market Cap

$188.9M 5.55%

24h Volume

$13.5M

Supplies

189.3M / ∞

Current Price

$1.099

7 Days
EURCV 7 days: -0.93%

Market Cap

$188.7M 0.27%

24h Volume

$39.4M

Supplies

171.7M / ∞

Current Price

$10.620

7 Days
DCR 7 days: -6.99%

Market Cap

$187.9M -1.46%

24h Volume

$370.7K

Supplies

17.7M / 21.0M

Current Price

$1.150

7 Days
BTSE 7 days: +4.57%

Market Cap

$186.5M 0.33%

24h Volume

$319.4K

Supplies

200.0M / 200.0M

Current Price

$54.920

7 Days
KOGE 7 days: -5.15%

Market Cap

$185.6M -0.47%

24h Volume

$22.4K

Supplies

3.4M / 3.4M

Current Price

$0.3636

7 Days
SHFL 7 days: -6.86%

Market Cap

$184.0M 1.95%

24h Volume

$395.1K

Supplies

917.5M / 1.0B

Current Price

$0.003605

7 Days
BEAM 7 days: -19.09%

Market Cap

$181.4M -6.17%

24h Volume

$6.8M

Supplies

57.5B / 57.5B

Current Price

$18.060

7 Days
COMP 7 days: -9.94%

Market Cap

$180.6M -0.48%

24h Volume

$7.4M

Supplies

10.0M / 10.0M

Current Price

$0.03383

7 Days
CFX 7 days: -15.38%

Market Cap

$177.7M -0.88%

24h Volume

$2.9M

Supplies

5.3B / ∞

Current Price

$1.100

7 Days
USTBL 7 days: +0.08%

Market Cap

$176.8M -0.12%

24h Volume

-

Supplies

160.2M / ∞

Current Price

$0.07711

7 Days
OP 7 days: -19.14%

Market Cap

$176.7M -0.84%

24h Volume

$21.6M

Supplies

4.3B / 4.3B

Notifications Login to see

Today

No Notifications

↑